At 8.2% CAGR, the North America Dental Bone Graft Substitute and Barrier Membrane Market is projected to be worth US$ 552.38 million by 2030, says Business Market Insights

According to Business Market Insights research, the North America dental bone graft substitute and barrier membrane market was valued at US$ 293.65 million in 2022 and is expected to reach US$ 552.38 million by 2030, registering a CAGR of 8.2% from 2022 to 2030. Increasing burden of periodontal diseases and oral cancer and strategic developments by market players are the critical factors attributed to the North America dental bone graft substitute and barrier membrane market expansion.

Periodontal range from simple gingivitis to serious conditions that cause significant damage to the soft tissues and bones supporting teeth; in a serious case, patients may lose their teeth. According to the World Health Organisation (WHO), as of 2023, ~3.5 billion people are affected with oral diseases across the world. Further, periodontal diseases affect 19% of the adult population, representing more than 1 billion cases. Poor oral hygiene and tobacco chewing are the main risk factors for periodontal disease. According to the article “The Link between Periodontal Disease and Oral Cancer—A Certainty or a Never-Ending Dilemma,” published by the Multidisciplinary Digital Publishing Institute (MDPI), more than 50% of the 18-year-old population in the US is likely to have periodontitis, and 75% of the population over 35 years is likely to be suffering from some form of periodontitis. As per an article published in the National Library of Medicine (NLM) in 2020, the risk of developing chronic systemic conditions such as autoimmune diseases and cancer increases with periodontitis. Several risk factors linked to periodontitis and oral cancer include smoking, alcohol consumption, and the human papillomavirus. According to the World Cancer Research Fund International, with ~377,700 cases recorded globally in 2020, lips and the oral cavity are the most common sites of mouth and oral cancer. The US Department of Health and Human Services states oral cancer accounts for ~3% of cancer cases diagnosed annually in the US alone. Further, ~48,000 people are diagnosed with oral cancer, and ~9,600 die of the condition each year in the country. According to the CDC, mouth and throat cancer cases accounted for 3% of cancer cases diagnosed annually in the US in 2020. Periodontal disease plays an important role in the development of oral squamous cell carcinoma (OSCC). According to the Global Cancer Observatory (GCO), the annual incidence of OSCC in 2020 was 377,713 cases globally, with the highest number recorded in Asia (248,360), followed by Europe (65,279) and North America (27,469), and the five-year prevalence of OSCC approached ~1 million globally. Further, the incidence of OSCC is expected to increase by up to 40% by 2040. A periodontal disease can lead to the resorption and failure of the alveolar bone, loss of periodontal attachment, and loosening and falling of the teeth. Therefore, the treatment of periodontal disease focuses on eliminating the source of infection, stimulating the synthesis of growth factors, and repairing periodontal tissue defects, ultimately restoring normal morphology and function. Correcting periodontal defects by bone grafting involves grafting materials (bone or bone substitutes) to restore the anatomical morphology of the alveolar bone and the function of the periodontal tissue. Therefore, the growing cases of periodontal diseases and oral cancer contribute to the growth of the North America dental bone graft substitute and barrier membrane market.

On the contrary, high cost of products & procedures and delays in dental check-ups hampers the North America dental bone graft substitute and barrier membrane market.

Based on product, the North America dental bone graft substitute and barrier membrane market has been bifurcated into dental bone graft substitutes and dental barrier membranes. The dental bone graft substitutes segment held 70.6% share of North America dental bone graft substitute and barrier membrane market in 2022, amassing US$ 207.21 million. It is projected to garner US$ 384.01 million by 2030 to expand at 8.0% CAGR during 2022–2030. 

Based on procedures, the North America dental bone graft substitute and barrier membrane market is segmented into guided bone regeneration (GBR) procedures, guided tissue regeneration (GTR) procedures, sinus-lift and ridge-split procedures, alveolar ridge preservation (ARP), block-graft procedures, periodontal regeneration procedures, socket preservation, and others. The sinus-lift and ridge-split procedures segment held 19.1% share of North America dental bone graft substitute and barrier membrane market in 2022, amassing US$ 55.97 million. It is projected to garner US$ 103.08 million by 2030 to expand at 7.9% CAGR during 2022–2030.

Based on end user, the North America dental bone graft substitute and barrier membrane market is segmented into hospitals, dental clinics, and others. The dental clinics procedures segment held 61.7% share of North America dental bone graft substitute and barrier membrane market in 2022, amassing US$ 181.24 million. It is projected to garner US$ 351.55 million by 2030 to expand at 8.6% CAGR during 2022–2030.

Based on country, the North America dental bone graft substitute and barrier membrane market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% share of North America dental bone graft substitute and barrier membrane market in 2022. It was assessed at US$ 248.93 million in 2022 and is likely to hit US$ 463.39 million by 2030, exhibiting a CAGR of 8.1% during the 2022-2030.      

Key players operating in the North America dental bone graft substitute and barrier membrane market are Geistlich Pharma AG, Medtronic Plc, Dentsply Sirona Inc, ZimVie Inc, Regenity Biosciences Inc, Neoss UK & Ireland Ltd, Institut Straumann AG, and Resorba Medical GmbH, among others.

• Straumann acquired GalvoSurge Dental AG, a Swiss medical device manufacturer. The acquired company has specialized in implant care and maintenance solutions, offering an innovative concept to support the treatment of peri-implantitis.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com